| Literature DB >> 34404224 |
Carissa M Baker-Smith, Amal Isaiah, Maria Cecilia Melendres, Joseph Mahgerefteh, Anayansi Lasso-Pirot, Shawyntee Mayo, Holly Gooding, Justin Zachariah.
Abstract
Obstructive sleep apnea (OSA) is a known risk factor for cardiovascular disease in adults. It is associated with incident systemic hypertension, arrhythmia, stroke, coronary artery disease, and heart failure. OSA is common in children and adolescents, but there has been less focus on OSA as a primary risk factor for cardiovascular disease in children and adolescents. This scientific statement summarizes what is known regarding the impact of sleep-disordered breathing and, in particular, OSA on the cardiovascular health of children and adolescents. This statement highlights what is known regarding the impact of OSA on the risk for hypertension, arrhythmia, abnormal ventricular morphology, impaired ventricular contractility, and elevated right heart pressure among children and adolescents. This scientific statement also summarizes current best practices for the diagnosis and evaluation of cardiovascular disease-related complications of OSA in children and adolescents with sleep apnea and highlights potential future research in the area of sleep-disordered breathing and cardiovascular health during childhood and adolescence.Entities:
Keywords: AHA Scientific Statements; arrhythmia; cardiovascular disease; left ventricular hypertrophy; obstructive sleep apnea; pediatric; sleep‐disordered breathing; systemic hypertension
Mesh:
Year: 2021 PMID: 34404224 PMCID: PMC8649512 DOI: 10.1161/JAHA.121.022427
Source DB: PubMed Journal: J Am Heart Assoc ISSN: 2047-9980 Impact factor: 6.106
Figure 1Sleep‐disordered breathing.
Obstructive sleep apnea syndrome. Adapted from Carroll. Copyright 2003, with permission from Elsevier.
Figure 2Partial and complete airway obstruction resulting in hypopnea and apnea, respectively.
Reprinted from Somers et al Copyright © 2008, American Heart Association, Inc. Adapted from Hahn and Somers. Copyright 2007, with permission from Elsevier.
Definition of Terms
| Term | Definition |
|---|---|
| Apnea | Repetitive interruption of ventilation during sleep caused by collapse of the pharyngeal airway. Cessation of airflow >2 breaths in duration for children and adolescents and >10 s for adults |
| AHI | Frequency of apneas and hypopneas per hour of sleep; measure of OSA severity |
| Arousal | Abrupt change in EEG frequency lasting at least 3 s with at least 10 s of stable sleep preceding the change, with concurrent increase in chin EMG for at least 1 s during REM sleep |
| Hypopnea | Reduction in airflow signal amplitude of at least 30%, in the presence of chest/abdominal wall motion, associated with oxygen desaturation of hemoglobin ≥3% or with an arousal |
| Hypoventilation | P |
| NREM sleep | NREM or quiet sleep |
| Obstructive hypoventilation | Gas exchange abnormalities without discrete obstructive apneas |
| OSA | Prolonged upper airway obstruction and intermittent complete obstructions leading to disruptions in normal ventilation during sleep |
| Polysomnography | Multichannel electrophysiologic recording that captures respiratory activity, EEG, EMG, and EOG recordings |
| Primary snoring | Snoring is a respiratory sound generated in the upper airway during sleep. Primary snoring is snoring that is not associated with apneas or gas exchange abnormalities. |
| REM sleep | REM or active sleep; associated with skeletal muscle atonia, rapid movements of the eyes, and dreaming |
| Sleep efficiency | Defined as the proportion of time spent asleep while in bed (or during recording time in a sleep study) |
| SDB | Defined by the degree of upper airway resistance, presence of sleep arousals, abnormalities in gas exchange, and apnea; includes primary snoring, upper airway resistance syndrome, obstructive hypoventilation, and OSA syndrome |
| Upper airway resistance syndrome | Increased upper airway resistance sufficient to degrade sleep quality; causes increased work of breathing leading to frequent arousals; no associated gas exchange abnormalities |
AHI indicates apnea‐hypopnea index; EEG, electroencephalographic; EMG, electromyogram/electromyographic; EOG, electrooculographic; NREM, nonrapid eye movement; OSA, obstructive sleep apnea; REM, rapid eye movement; and SDB, sleep‐disordered breathing.
Reprinted from Somers. Copyright © 2008, American Heart Association, Inc., and Bradley and Floras. Copyright © 2003, American Heart Association, Inc.
| Writing group member | Employment | Research grant | Other research support | Speakers' bureau/honoraria | Expert witness | Ownership interest | Consultant/advisory board | Other |
|---|---|---|---|---|---|---|---|---|
| Carissa M. Baker‐Smith | Nemours‐Alfred I. DuPont Hospital for Children | None | None | None | None | None | None | None |
| Justin Zachariah | Baylor College of Medicine, Texas Children's Hospital |
| None | None | None | None | None | None |
| Holly Gooding | Emory University School of Medicine | NHLBI (K23 Career Development Award) | None | None | None | None | None | None |
| Amal Isaiah | University of Maryland School of Medicine | NIH (coinvestigator for the Adolescent Brain and Cognitive Development Study) | None | None | None | Coinventor of ultrasound‐based imaging of sleep apnea; received patent royalties from University of Maryland | None | None |
| Anayansi Lasso‐Pirot | University of Maryland School of Medicine | None | None | None | None | None | None | None |
| Joseph Mahgerefteh | Icahn School of Medicine at Mount Sinai, New York | None | None | None | None | None | None | None |
| Shawyntee Mayo | University of Florida—Jacksonville | None | None | None | None | None | None | None |
| Maria Cecilia Melendres | Johns Hopkins University School of Medicine | None | None | None | None | None | None | None |
This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all members of the writing group are required to complete and submit. A relationship is considered to be “significant” if (1) the person receives $10 000 or more during any 12‐month period, or 5% or more of the person's gross income; or (2) the person owns 5% or more of the voting stock or share of the entity, or owns $10 000 or more of the fair market value of the entity. A relationship is considered to be “modest” if it is less than “significant” under the preceding definition.
Modest.
Significant.
| Reviewer | Employment | Research grant | Other research support | Speakers' bureau/honoraria | Expert witness | Ownership interest | Consultant/advisory board | Other |
|---|---|---|---|---|---|---|---|---|
| Raouf Amin | Cincinnati Children's Hospital Medical Center | None | None | None | None | None | None | None |
| Majaz Moonis | UMass Memorial Medical Center | None | None | None | None | None | None | None |
| Alberto R. Ramos | University of Miami | NIH | Jazz Pharmaceutical | None | None | None | None | None |
This table represents the relationships of reviewers that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all reviewers are required to complete and submit. A relationship is considered to be “significant” if (1) the person receives $10 000 or more during any 12‐month period, or 5% or more of the person's gross income; or (2) the person owns 5% or more of the voting stock or share of the entity, or owns $10 000 or more of the fair market value of the entity. A relationship is considered to be “modest” if it is less than “significant” under the preceding definition.
Significant.